Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$800M |
| 2 |
NVIDIA
NVDA
|
+$304M |
| 3 |
Broadcom
AVGO
|
+$261M |
| 4 |
Linde
LIN
|
+$237M |
| 5 |
JPMorgan Chase
JPM
|
+$208M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Costco
COST
|
+$656M |
| 2 |
Netflix
NFLX
|
+$632M |
| 3 |
Tesla
TSLA
|
+$474M |
| 4 |
Procter & Gamble
PG
|
+$428M |
| 5 |
Micron Technology
MU
|
+$332M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.04% |
| 2 | Healthcare | 15.35% |
| 3 | Industrials | 11.13% |
| 4 | Consumer Discretionary | 10.88% |
| 5 | Financials | 10.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CNTB
2776
Connect Biopharma Holdings
CNTB
$139M
| $316K | ﹤0.01% |
120,700
-22,400
| -16% | -$58.4K |
|
2777
Thryv Holdings
THRY
$166M
| $315K | ﹤0.01% |
115,113
-38,087
| -25% | -$150K |
|
2778
Bolt Biotherapeutics
BOLT
$7.32M
| $312K | ﹤0.01% |
77,225
+22,200
| +40% | +$116K |
|
2779
Energy Vault
NRGV
$589M
| $312K | ﹤0.01% |
94,495
-326,305
| -78% | -$1.35M |
|
|
PAL
2780
Proficient Auto Logistics
PAL
$193M
| $311K | ﹤0.01% |
45,900
-29,900
| -39% | -$247K |
|
|
CRDL
2781
Cardiol Therapeutics
CRDL
$142M
| $310K | ﹤0.01% |
+229,806
| New | +$236K |
|
2782
GEE Group
JOB
$23.4M
| $309K | ﹤0.01% |
1,288,926
+506,185
| +65% | +$118K |
|
2783
Vince Holding Corp
VNCE
$78M
| $308K | ﹤0.01% |
127,812
-9,638
| -7% | -$26.5K |
|
2784
Lipocine
LPCN
$18.1M
| $308K | ﹤0.01% |
38,497
+1,100
| +3% | +$9.58K |
|
2785
Liquidia Corp
LQDA
$7.92B
| $306K | ﹤0.01% |
8,100
-198,753
| -96% | -$7.37M |
|
2786
Dimensional International Core Equity 2 ETF
DFIC
$14.4B
| $306K | ﹤0.01% |
+8,600
| New | +$313K |
|
|
RAPP
2787
Rapport Therapeutics
RAPP
$1.98B
| $304K | ﹤0.01% |
9,700
-109,114
| -92% | -$3.07M |
|
2788
Transcontinental Realty Investors
TCI
$349M
| $303K | ﹤0.01% |
8,700
+200
| +2% | +$9.11K |
|
2789
Orchestra BioMed
OBIO
$218M
| $301K | ﹤0.01% |
70,900
-80,400
| -53% | -$342K |
|
|
THM
2790
International Tower Hill Mines
THM
$542M
| $298K | ﹤0.01% |
+129,595
| New | +$330K |
|
2791
FT Vest S&P 500 Dividend Aristocrats Target Income ETF
KNG
$3.35B
| $297K | ﹤0.01% |
+6,100
| New | +$310K |
|
2792
Nephros
NEPH
$40.9M
| $296K | ﹤0.01% |
99,400
-4,372
| -4% | -$17.5K |
|
2793
SOPHiA GENETICS
SOPH
$508M
| $296K | ﹤0.01% |
59,800
-23,200
| -28% | -$113K |
|
2794
Arts-Way Manufacturing Co
ARTW
$11.2M
| $296K | ﹤0.01% |
141,474
+17,000
| +14% | +$39.9K |
|
2795
JPMorgan Hedged Equity Laddered Overlay ETF
HELO
$4.14B
| $295K | ﹤0.01% |
4,621
-7,279
| -61% | -$482K |
|
2796
TherapeuticsMD
TXMD
$23.8M
| $295K | ﹤0.01% |
146,200
+49,700
| +52% | +$112K |
|
|
TVRD
2797
Tvardi Therapeutics
TVRD
$24M
| $293K | ﹤0.01% |
92,100
-12,400
| -12% | -$48.6K |
|
2798
WEX
WEX
$5.94B
| $291K | ﹤0.01% |
+1,900
| New | +$297K |
|
2799
GH Research
GHRS
$1.9B
| $290K | ﹤0.01% |
+20,614
| New | +$316K |
|
2800
Cineverse
CNVS
$57.6M
| $288K | ﹤0.01% |
120,096
-174,851
| -59% | -$422K |
|
Similar funds
Renaissance Technologies's Q1 2026 Portfolio in Review
As of Q1 2026, Renaissance Technologies held 3,809 positions worth $63.9B, down 0.82% from $64.5B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Renaissance Technologies's Q1 2026 filing shows 624 new, 1,320 increased, 1,262 reduced and 596 closed positions. Its largest new stake was Apple: 3,075,638 shares worth $781M. The largest sale was Costco, an estimated $656M.
By sector, the portfolio is most concentrated in Technology at 22% of assets, up from 21% a quarter earlier, followed by Healthcare and Industrials.
- Renaissance Technologies's largest Q1 2026 buy was Apple: 3,075,638 shares worth $781M.
- Renaissance Technologies added most to NVIDIA in Q1 2026, an estimated $304M increase.
- Renaissance Technologies's biggest Q1 2026 reduction was Costco, cutting an estimated $656M.
- Renaissance Technologies fully exited Procter & Gamble in Q1 2026, selling an estimated $428M.
- Renaissance Technologies's ten largest holdings make up 11% of its $63.9B portfolio in Q1 2026.
- Renaissance Technologies opened 624 new positions and closed 596 in Q1 2026.
- Renaissance Technologies's portfolio value fell 0.82% quarter-over-quarter to $63.9B.
Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.